Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

August 4, 2020 Bioscience

Melinta Therapeutics names Miller new CEO

PHOTO | Contributed Christine Ann Miller

New Haven-born antibiotics maker Melinta Therapeutics, under new ownership after emerging from bankruptcy in April, has a new top executive.

The company on Monday announced the appointment of veteran bioscience executive Christine Ann Miller as its president and CEO. 

Miller most recently led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, Melinta said. She also spent more than a decade at Actavis (now Allergan) and its predecessor Watson Pharmaceuticals, where she held leadership roles in R&D operations and supply chain management. 

In a statement, Miller said her immediate focus will be to accelerate the customer reach of Melinta's commercial antibiotics while expanding its portfolio “to serve the critical needs of patients in the hospital and hospital ecosystem.”

Miller succeeds Jennifer Sanfillippo, who had been serving as interim CEO since September 2019 following the departure of John Johnson. 

Sanfillippo, who led the company through bankruptcy this past spring, will resume her role as senior vice president and general counsel.

Melinta, now based in Morristown, N.J., became privately owned by affiliates of healthcare investment firm Deerfield Management Co. after emerging from bankruptcy in April. 

Contact Natalie Missakian at

Sign up for Enews


Order a PDF